ArticleJournal of Cancer2021
Pentraxin-3 inhibits milky spots metastasis of gastric cancer by inhibiting M2 macrophage polarization.
Article in Journal of Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- M2-polarized tumor-associated macrophages as key orchestrators of gastric cancer pathogenesis and therapeutic resistance.Discover oncology · 2026Review
- The role of tumor-associated macrophages in cancer development and their significance as prognostic markers.Clinical and experimental medicine · 2026Review
- Comprehensive multi-omics analysis reveals prognostic, immune, and therapeutic signatures of TNFAIP family genes in breast cancer.PloS one · 2026Article
- TRIM32 promotes tumor immune evasion and impedes Anti-PD-1 treatment by inducing immunosuppressive macrophages in gastric cancer.Journal of translational medicine · 2025Article
- Suppression of pentraxin 3 inhibits human osteosarcoma cell metastasis by repressing MAZ through STAT3 pathway.Cancer cell international · 2025Article
- The battle within: cell death by phagocytosis in cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- CHST1 as a prognostic-related biomarker in gastric cancer correlating with immune infiltration.Heliyon · 2025Article
- Clinical significance of the tumor microenvironment on immune tolerance in gastric cancer.Frontiers in immunology · 2025Review
- Single-cell sequencing reveals PTX3 involvement in ovarian cancer metastasis.Journal of ovarian research · 2024Article
- Inactivation of pentraxin 3 suppresses M2-like macrophage activity and immunosuppression in colon cancer.Journal of biomedical science · 2024Article
- The Role of Pentraxin 3 in Gastrointestinal Cancers.Cancers · 2023Review
- Role of long pentraxin PTX3 in cancer.Clinical and experimental medicine · 2023Review
- CAP2 promotes gastric cancer metastasis by mediating the interaction between tumor cells and tumor-associated macrophages.The Journal of clinical investigation · 2023Article
- Tumour-associated macrophages in gastric cancer: From function and mechanism to application.Clinical and translational medicine · 2023Review
- The Potential Use of Exosomes in Anti-Cancer Effect Induced by Polarized Macrophages.Pharmaceutics · 2023Review
- Research progress on the immune microenvironment and immunotherapy in gastric cancer.Frontiers in immunology · 2023Review
- Insights into the Relationship between Pentraxin-3 and Cancer.International journal of molecular sciences · 2022Review
- Tumor microenvironment-mediated immune tolerance in development and treatment of gastric cancer.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.